Navigation Links
Hospira Reports Second-Quarter 2009 Results
Date:7/29/2009

LAKE FOREST, Ill., July 29 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today reported results for the second quarter ended June 30, 2009. Net sales for the quarter were $957 million, and adjusted* diluted earnings per share were $0.73. (Adjusted* measures exclude certain specified items as described later in this press release and the attached schedules.)

"Hospira delivered a very good second quarter, marked by strong sales and earnings, and significant progress toward our Project Fuel initiatives," said Christopher B. Begley, chairman and chief executive officer. "Based on our results for the first half of the year and our expectations for the remainder of 2009, we have increased our full-year adjusted earnings guidance. We remain committed to improving shareholder value through sustainable top- and bottom-line growth."

Second-Quarter 2009 Results

The following table highlights selected financial results for the second quarter of 2009 compared to the same period in 2008: 

    In $ millions,              GAAP                     Adjusted*
     except per          Three Months Ended         Three Months Ended
     share amounts            June 30,                   June 30,
                          ----------------     %     ----------------     %
                           2009      2008   Change    2009      2008   Change
                          ------    ------  ------   ------    ------  ------
    Net Sales             $956.9    $901.6    6.1%     n/a       n/a     n/a
    Gross Profit
     (Net Sales
     less Cost of
     Products Sold)       $346.2    $335.2    3.3%   $365.8    $357.1    2.4%
    Income from
     Operations            $91.1    $117.7  (22.6
'/>"/>
SOURCE  Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 

Related medicine news :

1. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
2. Hospira to Present at the Credit Suisse Phoenix Health Care Conference on November 13
3. Hospira Reports Third-Quarter 2007 Results
4. Hospira to Present at the JPMorgan 26th Annual Healthcare Conference on January 9
5. Hospira Hosts Conference Call for Fourth-Quarter 2007 Results and 2008 Projections
6. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
7. Hospira Launches Generic Irinotecan Injection
8. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
9. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Hospira Acquires Sculptor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... disease had been treated, hadn,t spread, study finds , , ... reduce the risk of death in male colon cancer ... January 1986, included 668 men who,d been treated for ... that had not spread (nonmetastatic cancer). Every two years, ... any new cancer and disease diagnoses, as well as ...
(Date:12/14/2009)... But the bump in odds is small and shouldn,t ... (HealthDay News) -- Older women who take antidepressants may ... stroke and death compared to women not on the ... can be different from clinical significance," stressed Dr. Jordan ... Medical School, and lead author of a report in ...
(Date:12/14/2009)... Diego School of Medicine and Osaka University in Japan ... damage, including inflammation, fibrosis and cancer. The findings suggest ... works could lead to new insights into the development ... to be a master regulator of liver function," said ... of the UC San Diego School of Medicine. He ...
(Date:12/14/2009)... underdiagnosed, poorly treated and highly stigmatized, according to ... Rubin, M.D., Ph.D. So these Washington University physicians ... , In "Demystifying Psychiatry," Zorumski and Rubin, who ... psychiatric patients and helping patient families, say some ... treatment result from a lack of understanding psychiatry ...
(Date:12/14/2009)... perceived age to physical, mental functioning , , , MONDAY, ... than their age tend to live longer than those ... suggests. , The finding came from research that involved ... given physical and cognitive tests and then had their ... photos and indicated the age they perceived the participants ...
Breaking Medicine News(10 mins):Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3Health News:Scientists uncover protective mechanism against liver cancer 2Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3Health News:Looking Younger Than Your Age May Mean Longer Life 2
... N.C., Nov. 29 MedCath Corporation,(Nasdaq: MDTH ) ... the BMO Capital Markets 2007 Focus on Healthcare Conference,held ... Hotel in New York., MedCath,s senior management will ... am ET. The presentation will be web cast live ...
... Varian Medical,Systems (NYSE: VAR ) has ... for a major new hospital in,Portsmouth, England. In ... investment waves of the UK government,s Cancer Plan ... receive four high-energy,Clinac(R) iX linear accelerators equipped with ...
... Foundation(R) Finds Tobacco-Free,States Spend Less on Medicaid, ... nearly $10 billion less within five years if ... released today by the,American Legacy Foundation found that ... costs by 5.6 percent., The report, Saving ...
... (OA) of the hip is a growing problem that ... studies have reported on risk factors for developing OA, ... its prognosis. A new study published in the December ... examined patients with hip pain to determine their disease ...
... (NYSE:,CNO) said today that it has agreed to implement a ... (LTCG) for certain,back-office functions of the long term care business ... year that it was,considering this solution. Under the agreement:, ... call center and the processing ...
... 11:30 am ET, Thursday, Nov. 29, WASHINGTON, Nov. ... AIDS Alliance Fund:, WHAT: A press briefing by ... epidemic update as well as recently issued,proposals by several ... We will discuss what the new estimates of the ...
Other Medicine News:Health News:Varian Image-Guided Treatment Machines Selected for Major New Hospital on South Coast of England 2Health News:Varian Image-Guided Treatment Machines Selected for Major New Hospital on South Coast of England 3Health News:Smokers Cost Medicaid System Nearly $10 Billion 2Health News:Smokers Cost Medicaid System Nearly $10 Billion 3Health News:Identifying patients at high risk for total hip replacement 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 4Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 5
(Date:12/14/2009)... MOUNTAIN VIEW, Calif., Dec. 14 Alexza Pharmaceuticals, ... has submitted its New Drug Application (NDA) for Staccato® ... (FDA). AZ-004 is an inhalation product candidate being ... with schizophrenia or bipolar disorder. The IND for ... in August 2005. ,, "AZ-004 has delivered a predictable ...
(Date:12/14/2009)... Corgenix Medical Corporation (OTC Bulletin ... of diagnostic test kits, and BG Medicine, ... company, announced today a supply agreement whereby ... in enzyme-linked immunosorbent assay (ELISA) microtiter format ... seeking regulatory clearance in the United States ...
(Date:12/14/2009)... Southridge LLC ("Southridge"), an investment firm that provides ... announce that its affiliated fund has closed a private ... equity financing to Imaging Diagnostic Systems, Inc. (OTCBB: IMDS). ... growth of Imaging Diagnostic Systems, Southridge has paved a ... the field of early breast cancer detection," said Stephen ...
Breaking Medicine Technology:Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2Covering Kids 26 Families with Health Insurance is Goal of Back to School Outreach Campaign 54850 1Covering Kids 26 Families with Health Insurance is Goal of Back to School Outreach Campaign 54850 2New Jersey Surgery Centers Pick Health Informatics Consulting to Implement Patient Electronic Health Record Systems 13630 1New Jersey Surgery Centers Pick Health Informatics Consulting to Implement Patient Electronic Health Record Systems 13630 2Los Gatos Research Introduces Second Generation Liquid Water Isotope Analyzer 13628 1Los Gatos Research Introduces Second Generation Liquid Water Isotope Analyzer 13628 2
... Zevalin as consolidation therapy after remission induction in previously untreated patients ... ... July 22 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced today ... Administration (FDA) in September to,discuss the possibility of filing a supplemental Biologics ...
... of Oxford Clinical Trial,Service Unit and Epidemiological Studies ... SEAS trial of ezetimibe should be,tested by reviewing ... trials of ezetimibe, and reporting on the overall ... drug,manufacturers., The two hypothesis-testing trials (SHARP and ...
Other Medicine Technology:CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 2CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 3CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 4Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
BonePlast is a fast resorbing, osteoconductive bone void filler. By delivering a high dose of calcium to the operative site, BonePlast helps build new bone during the healing process. Packaged in a c...
LifeStent FlexStar delivery systems offer clinicians multiple methods for stent deployment to accommodate individual preference....
... Osteon 200R is a resorbable, osteoconductive matrix ... cleared for use in oral maxillofacial procedures ... faster-resorbing Pro Osteon 200R has been FDA ... resorbs and is replaced with bone during ...
Medicine Products: